Summit Therapeutics (SMMT) Capital Expenditures (2017 - 2026)

Summit Therapeutics (SMMT) has reported Capital Expenditures for 10 consecutive years, with $217000.0 the latest figure, recorded in Q2 2026.

• Quarterly Capital Expenditures fell 90.37% year-over-year to $217000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.8 million (down 128.34% YoY) and the FY2025 annual result came in at $657000.0, up 372.66% from the prior year.
• Capital Expenditures eased to $217000.0 in Q2 2026 per SMMT's latest filing, from $1.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for SMMT reached as high as $2.6 million in Q4 2024 and fell as low as -$3.9 million in Q4 2025.
• A 5-year average of $155055.6 and a median of $53000.0 in 2023 frame the typical range for Capital Expenditures.
• The largest YoY upside for Capital Expenditures was 129650.0% in 2024 against a maximum downside of 4715.09% in 2024.
• Year by year, Capital Expenditures stood at -$10000.0 in 2022, then jumped by 120.0% to $2000.0 in 2023, then surged by 129650.0% to $2.6 million in 2024, then plunged by 249.17% to -$3.9 million in 2025, then soared by 105.61% to $217000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $217000.0, $1.0 million, and -$3.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.